News
PACB
2.255
-7.20%
-0.175
Pacific Biosciences Q3: Another Revenue Guidance Cut
Seeking Alpha · 2d ago
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Seres Therapeutics (MCRB) and Relay Therapeutics (RLAY)
TipRanks · 3d ago
Pacific Biosciences Is Maintained at Underweight by Barclays
Dow Jones · 3d ago
Pacific Biosciences Price Target Raised to $2.00/Share From $1.25 by Barclays
Dow Jones · 3d ago
Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2
Benzinga · 3d ago
Pacific Biosciences Price Target Raised to $3.00/Share From $2.00 by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Reiterates Neutral on Pacific Biosciences, Raises Price Target to $3
Benzinga · 3d ago
PacBio (PACB) Q3 2026 Earnings Call Transcript
The Motley Fool · 3d ago
PacBio price target raised to $2 from $1.25 at Barclays
TipRanks · 3d ago
Barclays Keeps Their Sell Rating on Pacific Biosciences (PACB)
TipRanks · 3d ago
Pacific Biosciences of California, Inc. Announces CFO Transition and Reports Q3 2026 Financial Results
NASDAQ · 3d ago
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
NASDAQ · 4d ago
*Pacific Biosciences CFO Jim Gibson Steps Down, Mark Van Oene Named Interim CFO
Dow Jones · 4d ago
Pacific Biosciences Q3 2026 Earnings Call Transcript
Benzinga · 4d ago
PacBio narrows FY26 revenue view to $155M-$160M from $155M-$165M
TipRanks · 4d ago
PacBio Reports Third-Quarter Revenue Growth Amid Ongoing Losses
TipRanks · 4d ago
Pacific Biosciences of California Non-GAAP EPS of -$0.11 beats by $0.02, revenue of $40.6M beats by $1.14M
Seeking Alpha · 4d ago
*Pacific Biosciences 3Q Loss/Shr 12c >PACB
Dow Jones · 4d ago
*Pacific Biosciences 3Q Rev $40.6M >PACB
Dow Jones · 4d ago
*Pacific Biosciences 3Q Loss $37.8M >PACB
Dow Jones · 4d ago
More
Webull provides a variety of real-time PACB stock news. You can receive the latest news about Pacific Biosc through multiple platforms. This information may help you make smarter investment decisions.
About PACB
Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies.